A májfunkció romlásának rizikófaktorai sikeres vesetranszplantációt követően
| Autor: | Csilla Keresztes, Ferenc Rárosi, György Lázár, Tamás Várkonyi, Attila Nemes, Aurél Ottlakán, Csaba Lengyel, Bernadett Borda |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Hepatitis
medicine.medical_specialty business.industry Hepatitis C virus medicine.medical_treatment Immunosuppression General Medicine medicine.disease_cause medicine.disease Gastroenterology Tacrolimus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Internal medicine Hyperlipidemia medicine Uric acid 030211 gastroenterology & hepatology Liver function business Kidney transplantation |
| Zdroj: | Orvosi Hetilap. 160:186-190 |
| ISSN: | 1788-6120 0030-6002 |
| DOI: | 10.1556/650.2019.31257 |
| Popis: | Abstract: Introduction: Increase of liver function is one of the most common complications after kidney transplantation due to the use of immunosuppressive therapy and hyperlipidemia in addition to hepatitis C virus (HCV) infection. Method: Following the selection criteria (n = 59), the study is based on applied immunosuppressive therapy, baseline data of patients, further correlation between HCV and liver function deterioration. Patients were subjected to fasting laboratory examination to monitor serum electrolytes, uric acid and albumin levels. We looked at the effects of immunosuppressive therapy on the lipids (TG, TC, HDL, LDL) and liver enzymes (GOT, GPT, ALP, GGT). The analysis of the relationship between lipids and liver enzymes was also included in our study. Results: The data basics were not significantly different between the tacrolimus and the cyclosporine groups. In the laboratory results, Mg levels were significantly different between the two groups (p = 0.044). The impact of HCV on the liver function was significantly different on GGT (p = 0.008). We examed the lipids and liver function level between the tacrolimus and the patients receiving cyclosporine-based immunosuppression and the total cholesterol (p = 0.005) and GOT (p = 0.05) were significantly different between the two groups. Hyperlipidemia was associated with 26% of patients taking tacrolimus-based immunosuppression, and 89% of those receiving cyclosporine; the difference was significant (p = 0.002). Regarding the effect of hyperlipidemia on liver enzymes, ALP (p = 0.006) and GGT (p = 0.0001) were significantly higher. Conclusion: Increases in hepatic enzymes, ALT and GGT indicate the damage to hepatocytes. Beside the increase of liver function, which is the main risk factor in hepatitis on HCV soil, the applied immunosuppressive therapy and hyperlipidemia lead to degradation of allograft function and long-term graft loss. Orv hetil. 2019; 160(5): 186–190. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|